Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase II Study of Intravenous Rexin-G in Osteosarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00572130
Recruitment Status : Completed
First Posted : December 12, 2007
Last Update Posted : June 10, 2011
Information provided by:
Epeius Biotechnologies

Brief Summary:
Rexin-G is a tumor-targeted gene medicine that is designed to seek out and destroy both primary tumors and metastatic cancers without the side effects of standard chemotherapy. The objectives of the study are: (1) to evaluate the clinical effectiveness of intravenous injections of Rexin-G, a tumor-targeted gene vector, in controlling tumor growth and prolonging life, and (2) to evaluate its over-all safety.

Condition or disease Intervention/treatment Phase
Osteosarcoma Genetic: Rexin-G Dose 1 Genetic: Rexin-G Dose 2 Phase 2

Detailed Description:

The adaptive trial design of this advanced Phase II study incorporates (i) a dosing schedule based on the patient's estimated tumor burden and not on standard dosing per kilogram body weight or body surface area, and (2) a tumor response evaluation process that is unique to the manner in which osteosarcoma responds favorably to therapy, i.e., with necrosis and increasing calcification in metastatic tumors and decreased glucose utilization using PET-CT imaging studies.

Twenty to thirty patients will receive Rexin-G at either Dose Level 1 or 2. Patients will be assigned a dose level based on the estimated tumor burden as measured by PET-CT imaging studies. Estimated tumor burden is measured by multiplying the sum of the longest diameters of target lesions in cm by 10e9 cancer cells. If the tumor burden is less than 10 billion cells, the patient will be assigned to Dose Level 1, if the tumor burden is greater than 10 billion cells, the patient will be assigned to Dose Level 2.

*Treatment Cycle Dose Level Vector Dose/Day Max.Volume/Dose

Two times a week 1 1.0 x 10e11 cfu 200 ml

Three times a week 2 1.0 x 10e11 cfu 200 ml

* Each treatment cycle will be six weeks (four weeks of treatment and two weeks of rest). Patients who have resolution of toxicity to < grade I may have repeat cycles. After one or more treatment cycles, the principal investigator may recommend surgical debulking or complete surgical removal. If residual disease is present either by histopathological examination or by PET-CT scan, repeat treatment cycles may be given 3-4 weeks after surgery, if the surgical incision has healed, and if the patient has < grade I toxicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Intravenous Rexin-G in Recurrent or Metastatic Osteosarcoma
Study Start Date : December 2007
Actual Primary Completion Date : July 2010
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Rexin-G Dose 1 Genetic: Rexin-G Dose 1
Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity

Experimental: Rexin-G Dose 2 Genetic: Rexin-G Dose 2
Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity

Primary Outcome Measures :
  1. Clinical efficacy as measured by over-all response rates (either CR, PR or SD) by International PET criteria [ Time Frame: 12-18 months ]

Secondary Outcome Measures :
  1. Clinical efficacy as measured by progression-free survival greater than one month and over-all survival of 6 months or longer; clinical toxicity measures [ Time Frame: 12-18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient with recurrent or metastatic osteosarcoma who is considered refractory to known therapies.
  2. Histologically or cytologically confirmed osteosarcoma that is measurable.
  3. Adequate hepatic function: Total bilirubin < 2.0 mg/dL (upper limit included); AST/ALT < 2x institutional norm; alkaline phosphatase < 2.5x upper limit of institutional norm unless the patient has extensive bone metastases. Patients with elevated alkaline phosphatase due to extensive liver disease will be excluded from study; albumin > 3.0 mg/dL. There must be no substantial ascites. PT and PTT must be within normal limits.
  4. Performance status must be < 1 (ECOG 0-1) with a life expectancy of at least 3 months.
  5. Hemoglobin > 9 gms%
  6. Absolute granulocyte count > 1000/uL, and platelet count > 100,000/uL.
  7. Serum creatinine of less than 1.5 mg%.
  8. There must be no plans for the patient to receive further cancer therapy from the date of enrollment until the completion of the 6-week follow-up visit.
  9. Accessibility of peripheral or central IV line
  10. Age > 10 years
  11. Patients will be off chemotherapy for a minimum of 4 weeks prior to initiation of therapy and should have recovered to Grade 1 or less toxicity.
  12. The ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Prior malignancy, except for non-melanoma skin cancer, stage 1 breast cancer, CIS of cervix from which the patient has been disease-free for 5 years.
  2. Woman who are pregnant or nursing
  3. Fertile patients unless they agree to use barrier contraception (condoms and spermicide jelly) during the vector infusion period and for six weeks after infusion. Male patients must agree to use barrier contraception.
  4. Patients who are transfusion dependent (more than one transfusion per month)
  5. Patients with medical, psychiatric, or social conditions that would compromise successful adherence to this protocol.
  6. Patient who do not meet the inclusion criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00572130

Layout table for location information
United States, California
Epeius Clinical Research Unit/Sarcoma Oncology Center
Los Angeles, California, United States, 91108
Sponsors and Collaborators
Epeius Biotechnologies
Layout table for investigator information
Principal Investigator: Sant P Chawla, M.D. Epeius Clinical Research Unit/Sarcoma Oncology Center
Layout table for additonal information
Responsible Party: Erlinda M. Gordon, M.D., Epeius Biotechnologies Corporation Identifier: NCT00572130    
Other Study ID Numbers: C07-110
First Posted: December 12, 2007    Key Record Dates
Last Update Posted: June 10, 2011
Last Verified: February 2010
Keywords provided by Epeius Biotechnologies:
Tumor-targeted gene medicine
Cyclin G1 gene
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type